TY - JOUR T1 - Spectral-domain optical coherence tomography in subjects over 60 years of age, and its implications for designing clinical trials JF - British Journal of Ophthalmology JO - Br J Ophthalmol SP - 533 LP - 533 DO - 10.1136/bjophthalmol-2012-302923 VL - 97 IS - 4 AU - Oliver Comyn AU - Catey Bunce AU - Praveen J Patel AU - Caroline J Doré Y1 - 2013/04/01 UR - http://bjo.bmj.com/content/97/4/533.abstract N2 - We read with interest the paper by Caramoy et al recently published in the British Journal of Ophthalmology—our attention having been captured by the inclusion of clinical trial design in its title.1 Developments in stem cell treatments and the advent of anti-vascular endothelial growth factor treatments have very much placed ophthalmic clinical trials in the public arena. We feel however that the main conclusion drawn by the authors that ‘clinical trials using central retinal thickness as an endpoint are feasible in terms of sample size needed’ needs to be tempered in the light of the following issues. Power: Designing a clinical trial with 80% power means that there is a 20% chance of missing … ER -